Summit Therapeutics is a biotechnology business based in the US. Summit Therapeutics shares (SMMT) are listed on the NASDAQ and all prices are listed in US Dollars. Summit Therapeutics employs 105 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $12.27 |
|---|---|
| 52-week range | $1.61 - $21.50 |
| 50-day moving average | $10.49 |
| 200-day moving average | $5.78 |
| Wall St. target price | $12.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.11 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $12.27 from 2024-09-06
| 1 week (2024-09-03) | -2.62% |
|---|---|
| 1 month (2024-08-09) | 13.82% |
| 3 months (2024-06-10) | 53.76% |
| 6 months (2024-03-08) | 178.86% |
| 1 year (2023-09-08) | 696.75% |
|---|---|
| 2 years (2022-09-09) | 851.16% |
| 3 years (2021-09-10) | 88.77% |
| 5 years (2019-09-10) | 793.53% |
| Gross profit TTM | $705,000 |
|---|---|
| Return on assets TTM | -31.01% |
| Return on equity TTM | -102.77% |
| Profit margin | 0% |
| Book value | $0.27 |
| Market Capitalization | $8.9 billion |
TTM: trailing 12 months
We're not expecting Summit Therapeutics to pay a dividend over the next 12 months.
Summit Therapeutics's shares were split on 20 September 2020.
Over the last 12 months, Summit Therapeutics's shares have ranged in value from as little as $1.61 up to $21.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Summit Therapeutics's is -1.002. This would suggest that Summit Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Summit Therapeutics has bucked the trend.
Summit Therapeutics Inc. , a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida. .
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.